Merck & Co to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead Sciences Inc - Conference Call Transcript
Good morning. My name is Laura, and I will be your conference operator today. At this time, I would like to welcome everyone as Merck Announces HIV Collaboration with Gilead. (Operator Instructions)
I would now like to turn the call over to Peter Dannenbaum, Vice President, Investor Relations. Sir, please go ahead.
Thank you, Laura, and good morning. Welcome to Merck's call to discuss today's announcement of collaboration with Gilead Sciences as well as our HIV program broadly. Our speakers today will be Dr. Dean Li, President of Merck Research Labs; Dr. Daria Hazuda, Head of Infectious Disease Discovery and Research; Dr. Roy Baynes, Chief Medical Officer of Merck Research Labs and Head of Clinical Development; and Frank Clyburn, our Chief Commercial Officer.
I would like to remind you that some of the statements that we make during today's call may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
